Zai Lab Limited (HKG:9688)
21.80
-1.04 (-4.55%)
Oct 23, 2025, 4:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $109.98M USD in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $427.80M, up 32.56% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$427.80M
Revenue Growth
+32.56%
P/S Ratio
7.49
Revenue / Employee
$228.89K
Employees
1,869
Market Cap
25.15B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
JD Health International | 71.34B |
BeOne Medicines AG | 35.81B |
Sino Biopharmaceutical | 33.49B |
Alibaba Health Information Technology | 32.81B |
CSPC Pharmaceutical Group | 28.49B |
WuXi Biologics | 21.98B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
Zai Lab News
- 8 days ago - Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - Business Wire
- 8 days ago - Zai Lab (ZLAB) Stock Declines Nearly 7% - GuruFocus
- 10 days ago - Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
- 6 weeks ago - Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
- 6 weeks ago - Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
- 6 weeks ago - China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order - Investor's Business Daily
- 6 weeks ago - Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB - GlobeNewsWire